Veterinary Pathology · 2005 · 72 citations · 22 references
MedicineOncologyVeterinary PathologyCarcinogenesisNeoplasiaTumor PathologyCancer Molecular PathologyImmunohistochemistryCanine Mammary TumorCanine Tumor PathologyCyclooxygenase IsoformsHistologic Tumor ClassificationImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical Staining
Cyclooxygenase-2 (COX-2) is an inducible member of the family of cyclooxygenase enzymes that has been implicated in the genesis of numerous cancers. The role of COX-2 in canine mammary neoplasia remains to be more clearly elucidated. The goal of the study reported here was to determine whether a direct association between levels of COX-2 expression and tumor histologic subtype exists in canine mammary carcinoma. Immunohistochemical analysis was performed using a polyclonal antiprostaglandin G/H synthase 2 IgG COX-2 antibody. Sections from the kidneys of young dogs, which stain positive for COX-2 in the macula densa, served as positive controls. Slides were reviewed by a single pathologist, and were evaluated for COX-2 expression according to previously established scales. Positive-staining tumors were given a COX-2 staining distribution (on the basis of the percentage of positive staining cells in five 400x fields) and intensity score according to previously established scales. The product of the COX-2 staining distribution and intensity scores was calculated to create a COX-2 staining index. COX-2 expression was detected in 28 of 50 (56%) samples evaluated. Anaplastic carcinomas had a significantly higher COX-2 staining distribution, intensity, and index, compared with those for adenocarcinomas (P < 0.0001). The overall percentage of positive tumors (56%) was consistent with that of prior studies. To the authors' knowledge, these results indicate, for the first time, a direct association between COX-2 expression and tumor histologic subtype in canine mammary carcinomas. Future research directed at measuring tumor response in canine mammary carcinoma patients treated with a selective COX-2 inhibitor is indicated.
22
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ari Ristimäki, Anna Sivula, Johan Lundin et al. · PubMed · 2002 · 787 citations
Medicine, Cancer Biology, Oncology +16
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.
Fadlo R. Khuri, Hong Wu, B L Kemp et al. · PubMed · 2001 · 412 citations
Robert J. Schneider, C. Richard Dorn, Dee O. N. Taylor · JNCI Journal of the National Cancer Institute · 1969 · 362 citations
Prognostic Factors in Canine Mammary Tumors: A Multivariate Study of 202 Consecutive Cases
Eva Hellmén, R. Bergström, Lars Holmberg et al. · Veterinary Pathology · 1993 · 191 citations